Glenmark Pharmaceuticals will conduct an earnings call to discuss the unaudited financial results for the quarter ended June 30, 2026. The conference is scheduled for August 3, 2026, providing investors and analysts an opportunity to review the company's performance for Q1 FY27.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call will be led by the company's management to address queries regarding the financial results.

Earnings Call Details

The event is structured to facilitate a detailed discussion on the quarterly performance. Participants can join the session using the specific access numbers allocated for different regions.

Access Information

Global participants can access the call through the following dial-in numbers:

• India: +91 22 6280 1298, +91 22 7115 8199
• USA: 1 866 746 2133
• UK: 0 808 101 1573
• Singapore: 800 101 2045
• Hong Kong: 800 964 448

Pre-registration for the event is available online. For further clarification, stakeholders may contact Utkarsh Gandhi via email at utkarsh.gandhi3@glenmarkpharma.com or phone at +91 22 4018 9232.

Glenmark Pharmaceuticals received approval from the U.S. FDA to expand the use of RYALTRIS Nasal Spray for the treatment of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. The approval strengthens the company's innovative respiratory portfolio following its transition to direct commercialization in the United States. RYALTRIS is now approved for adults and pediatric patients aged 6 years and older.

The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis. The study demonstrated that RYALTRIS improved nasal symptoms compared with placebo and was well tolerated over the 14-day treatment period. According to the U.S. Centers for Disease Control and Prevention, 25% of children aged 6 to 11 years had a diagnosed seasonal allergy in 2024.

Effective April 1, 2026, Glenmark Pharmaceuticals Inc., USA assumed responsibility for the end-to-end commercialization and distribution of RYALTRIS in the United States. The company now directly leads the product's brand strategy, market access, distribution, and customer engagement.

Product Details

RYALTRIS is a fixed-dose combination nasal spray containing olopatadine hydrochloride and mometasone furoate. It combines an antihistamine and a corticosteroid in a single formulation. The drug was initially approved by the U.S. FDA in 2022 for adults and pediatric patients 12 years of age and older.

Global Presence

RYALTRIS has established a broad international footprint with approvals across key markets including the European Union, United Kingdom, Australia, South Korea, Russia, and China. In FY26, RYALTRIS was launched in 11 additional markets, expanding its global presence to 56 countries.

Marc Kikuchi, President & Business Head, North America, stated that the approval marks an important step in expanding access to RYALTRIS. He added that the transition to direct commercialization enables closer engagement with healthcare professionals and patients to build the franchise.